InvestorsHub Logo
Followers 617
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: Cookiepants post# 5637

Wednesday, 07/09/2014 4:54:09 PM

Wednesday, July 09, 2014 4:54:09 PM

Post# of 6599
The timing of that article was very unfortunate. However, those that bought and experienced the drop had opportunity to get out when it came back up. I suspect many did.

The IND should be filed in less than a year. We'll get an update on when sometime next quarter. The FDA asking for the additional pre clinicals put things back by quite a bit. However, they are getting good results.

International Stem Cell Corporation Completes Important Study in Parkinson's Disease Program

http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=70827&GoTopage=1&Category=958&BzID=1468&G=583

CARLSBAD, CA--(Marketwired - Jun 19, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, announced today the completion of the acute toxicity study of the Company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The Company intends to provide a further update early next quarter.




International Stem Cell Corporation Signs Agreement Including Certain Terms for a Definitive License Agreement With Rohto Pharmaceutical Co., Ltd. of Japan

http://www.internationalstemcell.com/profiles/investor/ResLibraryView.asp?ResLibraryID=71067&GoTopage=1&Category=958&BzID=1468&G=583

This is huge since it is my understanding that Japan is a huge market for the Lifeline human cell products. This is just more indication that the cell line subsidiary should continue to grow.

Plus, there is at least one European human trial that I'm aware of using ISCO stem cell product. If any of those therapies are approved for use there will be a huge increase in product purchase from Lifeline.

A lot is moving forward.





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ISCO News